11
|
Naito AT, Okada S, Minamino T, Iwanaga K, Liu ML, Sumida T, Nomura S, Sahara N, Mizoroki T, Takashima A, Akazawa H, Nagai T, Shiojima I, Komuro I. Promotion of CHIP-Mediated p53 Degradation Protects the Heart From Ischemic Injury. Circ Res 2010; 106:1692-702. [DOI: 10.1161/circresaha.109.214346] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Rationale
:
The number of patients with coronary heart disease, including myocardial infarction, is increasing and novel therapeutic strategy is awaited. Tumor suppressor protein p53 accumulates in the myocardium after myocardial infarction, causes apoptosis of cardiomyocytes, and plays an important role in the progression into heart failure.
Objectives
:
We investigated the molecular mechanisms of p53 accumulation in the heart after myocardial infarction and tested whether anti-p53 approach would be effective against myocardial infarction.
Methods and Results
:
Through expression screening, we found that CHIP (carboxyl terminus of Hsp70-interacting protein) is an endogenous p53 antagonist in the heart. CHIP suppressed p53 level by ubiquitinating and inducing proteasomal degradation. CHIP transcription was downregulated after hypoxic stress and restoration of CHIP protein level prevented p53 accumulation after hypoxic stress. CHIP overexpression in vivo prevented p53 accumulation and cardiomyocyte apoptosis after myocardial infarction. Promotion of CHIP function by heat shock protein (Hsp)90 inhibitor, 17-allylamino-17-demethoxy geldanamycin (17-AAG), also prevented p53 accumulation and cardiomyocyte apoptosis both in vitro and in vivo. CHIP-mediated p53 degradation was at least one of the cardioprotective effects of 17-AAG.
Conclusions
:
We found that downregulation of CHIP level by hypoxia was responsible for p53 accumulation in the heart after myocardial infarction. Decreasing the amount of p53 prevented myocardial apoptosis and ameliorated ventricular remodeling after myocardial infarction. We conclude that anti-p53 approach would be effective to treat myocardial infarction.
Collapse
Affiliation(s)
- Atsuhiko T. Naito
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Sho Okada
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Tohru Minamino
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Koji Iwanaga
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Mei-Lan Liu
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Tomokazu Sumida
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Seitaro Nomura
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Naruhiko Sahara
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Tatsuya Mizoroki
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Akihiko Takashima
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Hiroshi Akazawa
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Toshio Nagai
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Ichiro Shiojima
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| | - Issei Komuro
- From the Department of Cardiovascular Science and Medicine (A.T.N., S.O., T. Minamino, K.I., M.-L.L., T.S., S.N., H.A., T.N., I.S., I.K.), Chiba University Graduate School of Medicine, Japan; Department of Cardiovascular Medicine (A.T.N., H.A., I.S., I.K.), Osaka University Graduate School of Medicine, Japan; PRESTO (T. Minamino), Japan Science and Technology Agency, Saitama, Japan; and Laboratory for Alzheimer’s Disease (N.S., T. Mizoroki, A.T.). RIKEN Brain Science Institute, Saitama, Japan
| |
Collapse
|